Fig. 9From: Improving cancer detection through combinations of cancer and immune biomarkers: a modelling approacha Regions of malignant vs. benign tumour predictions in the (IL-7, CA-125) parameter space, as proposed in the clinical study by [14]. b(i) Regions of healthy vs. cancerous states in the (IL-7, CA-125) phase plane, as predicted by the numerical simulations; (ii) tumour size versus the immune biomarker (IL-7) level (the dotted vertical line shows the IL-7 detection threshold, while the dashed horizontal line shows tumour size at the detection time); (iii) tumour size versus the cancer biomarker (CA-125) level (the dotted horizontal line shows the CA-125 detection threshold, while the dashed vertical line shows tumour size at the detection time). The blue arrows on the solution curves show the increase in timeBack to article page